In today’s pharma landscape, patient convenience and drug delivery innovation go hand in hand. But how do you deliver life-saving biologics at higher concentrations without sacrificing safety, stability, or patient comfort?
In this live-recorded episode of Life Science Solutions, host Chris Adkins sits down with Ryan Doxey, Vice President of Technical Services at Kymanox, for part one of their conversation together. Ryan unpacks the opportunities and challenges of hyper-concentrated formulations, from why patients stand to benefit to how technical hurdles like viscosity, stability, and scale-up shape the path forward.
Chris and Ryan dig into what makes high-concentration biologics both technically challenging and clinically promising.
Topics Include:
Why high-concentration biologics matter for patient convenience and compliance
The science of formulation: balancing potency, viscosity, and stability
Scale-up and manufacturing barriers innovators must solve
Lifecycle management and the competitive edge of delivery innovation
This is part one of a two-part conversation with Ryan Doxey, offering an inside look at how advanced biologics are being reimagined for the patients who need them most.
📍 Recorded live during the Podcast Marathon at Walk West studio in Raleigh North Carolina.
Podden och tillhörande omslagsbild på den här sidan tillhör
Kymanox. Innehållet i podden är skapat av Kymanox och inte av,
eller tillsammans med, Poddtoppen.
